Experts discuss PD-L1 testing for HER2-positive metastatic gastric cancer as new trial data shifts immunotherapy timing
The HERIZON-GEA-01 trial outlines its design and geographic enrollment while focusing on PD-L1 testing in HER2-positive metastatic gastric cancer.
Clinicians and researchers are debating the role of PD-L1 testing, questioning how it should guide treatment decisions in this patient population.
Recent data from the study suggest that the timing of adding immunotherapy may need to be reconsidered, prompting a reassessment of current protocols.
The discussion highlights the need for clearer guidelines on biomarker testing and integration of immunotherapy for HER2-positive gastric cancer patients.
This writeup was produced by pharmadog from original reporting by onclive.
Original headline: “HERIZON-GEA-01 Study Design, Geographic Distribution, and PD-L1 Testing Considerations”
read at onclive ↗
comments(0)
5-min edit window · permanent after that